Researchers conducted the study for analyzing the effect of pregnancy on management decisions of melanoma patients treated at NYU Langone Health (NYULH).
Publications
Gender differences in cutaneous melanoma: Demographics, prognostic factors, and survival outcomes
Researchers used the National cancer database to determine the features of melanoma that contribute to overall survival (OS) of women living in the United States.
Disparities in the occurrence of late effects following treatment among adolescent and young adult melanoma survivors
Given that melanoma is the third most common cancer in the adolescent and young adult (AYA) population, researchers conducted this investigation to analyze the occurrence of adverse health conditions following melanoma treatment in these survivors.
Melanoma Research Alliance Hails FDA’s First ‘Triplet’ Combination Approval for Melanoma
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the decision by the U.S. Food and Drug Administration (FDA) approving Genentech’s Tecentriq ® (atezolizumab) plus Cotellic ® (cobimetinib) and Zelboraf ® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.